Unknown

Dataset Information

0

Osthole inhibits triple negative breast cancer cells by suppressing STAT3.


ABSTRACT: BACKGROUND:Triple-negative breast cancer (TNBC) is an aggressive subgroup of human breast cancer. Patients with TNBC have poor clinical outcome as they are non-responsive to current targeted therapies. There is an urgent need to identify new therapeutic targets and develop more effective treatment options for TNBC patients. Osthole, a natural product from C. monnieri, has been shown to inhibit certain cancer cells. However, the mechanisms of action as well as its effect on TNBC cells are not currently known. METHODS:We investigated the effect of osthole in cultured TNBC cells as well as in a xenograft model of TNBC growth. We also used a high-throughput proteomics platform to identify the direct binding protein of osthole. RESULTS:We found that osthole inhibited the growth of a panel of TNBC cells and induced apoptosis in both cultured cells and TNBC xenografts. We used a high-throughput proteomics platform and identified signal transducer and activator of transcription 3 (STAT3) as a potential binding protein of osthole. We further show that osthole suppressed STAT3 in TNBC cells to inhibit growth and induce apoptosis. Overexpressing STAT3 in TNBC reduced the effectiveness of osthole treatment. CONCLUSIONS:These results provide support for osthole as a potential new therapeutic agent for the management of TNBC. Moreover, our results indicate that STAT3 may be targeted for the development of novel anti-TNBC drugs.

SUBMITTER: Dai X 

PROVIDER: S-EPMC6303899 | biostudies-other | 2018 Dec

REPOSITORIES: biostudies-other

altmetric image

Publications

Osthole inhibits triple negative breast cancer cells by suppressing STAT3.

Dai Xuanxuan X   Yin Changtian C   Zhang Yi Y   Guo Guilong G   Zhao Chengguang C   Wang Ouchen O   Xiang Youqun Y   Zhang Xiaohua X   Liang Guang G  

Journal of experimental & clinical cancer research : CR 20181222 1


<h4>Background</h4>Triple-negative breast cancer (TNBC) is an aggressive subgroup of human breast cancer. Patients with TNBC have poor clinical outcome as they are non-responsive to current targeted therapies. There is an urgent need to identify new therapeutic targets and develop more effective treatment options for TNBC patients. Osthole, a natural product from C. monnieri, has been shown to inhibit certain cancer cells. However, the mechanisms of action as well as its effect on TNBC cells are  ...[more]

Similar Datasets

| S-EPMC6558915 | biostudies-literature
| S-EPMC6945120 | biostudies-literature
| S-EPMC5352123 | biostudies-literature
| S-EPMC5768915 | biostudies-literature
| S-EPMC5108677 | biostudies-literature
| S-EPMC5352396 | biostudies-literature
| S-EPMC7810837 | biostudies-literature
| S-EPMC6941134 | biostudies-literature
| S-EPMC3235255 | biostudies-literature
| S-EPMC5435721 | biostudies-literature